U.S. markets close in 16 minutes
  • S&P 500

    4,478.22
    -2.48 (-0.06%)
     
  • Dow 30

    34,805.57
    -8.82 (-0.03%)
     
  • Nasdaq

    15,184.86
    +23.33 (+0.15%)
     
  • Russell 2000

    2,237.16
    +2.71 (+0.12%)
     
  • Crude Oil

    72.65
    +0.04 (+0.06%)
     
  • Gold

    1,755.20
    -39.60 (-2.21%)
     
  • Silver

    22.91
    -0.89 (-3.74%)
     
  • EUR/USD

    1.1769
    -0.0057 (-0.48%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • GBP/USD

    1.3791
    -0.0044 (-0.32%)
     
  • USD/JPY

    109.7180
    +0.3580 (+0.33%)
     
  • BTC-USD

    47,714.15
    -437.48 (-0.91%)
     
  • CMC Crypto 200

    1,225.95
    -7.34 (-0.60%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.37 (-0.62%)
     

Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:30 a.m. ET.

The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.

About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com